Trilaciclib with chemoradiation and immunotherapy for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests an investigational drug called trilaciclib added to standard chemoradiation and immunotherapy for locally advanced esophageal cancer that cannot be surgically removed. The goal is to see if this combination improves treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have squamous cell carcinoma of the esophagus that is locally advanced (stage II–IV) and cannot be removed by surgery, or you have refused surgery.
- You have at least one tumor that can be measured on scans (CT or MRI).
- You have not had any prior chemotherapy, radiation, immunotherapy, or other cancer treatment for this condition.
- You are in good general health (ECOG performance status 0 or 1), meaning you are fully active or limited only in strenuous activity.
- Your kidney, liver, and blood counts meet specific thresholds (e.g., adequate neutrophil count, hemoglobin, and platelet levels).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called trilaciclib that is given before chemoradiation to help protect your bone marrow and reduce side effects like low blood counts. It is for people with a specific type of esophageal cancer who have finished their main treatment.
This trial tests a combination of radiation, chemotherapy (cisplatin and paclitaxel), and an immunotherapy drug called camrelizumab for patients with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if adding immunotherapy improves outcomes compared to standard treatment alone.
This trial tests if giving chemotherapy and radiation before surgery, followed by immunotherapy, can improve outcomes for people with a specific type of esophageal cancer that can be surgically removed.
This trial tests combining the immunotherapy drug carrelizumab with standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this combination can help shrink or control the tumor.
This trial tests a new drug called Trilaciclib added to standard cancer immunotherapy and chemotherapy for people with recurrent or metastatic head and neck squamous cell carcinoma that cannot be treated with surgery or radiation. The goal is to see if adding Trilaciclib helps protect the body's blood cells during treatment.
This study tests whether adding trilaciclib to a new chemotherapy (sacituzumab tirumotecan) can help people with EGFR-mutant lung cancer that keeps growing after certain targeted treatments. The goal is to see if it slows the cancer and reduces side effects.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.